We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks Ralph
Appreciate
From their RNS March 2nd 2022.
Physiomics will be supporting Ankyra with modelling and simulation of ANK-101 in immune-oncology settings in support of its early development.
https://www.physiomics.co.uk/contract-award-9/
Kudos to PYC for helping Ankara and other clients get drugs to this stage quicker and with more precision. Wonder if PYC could start to do more revenue sharing models with future contracts ?
Ankyra has conducted an exploratory study of JEN-101 in dogs with advanced melanoma. “The canine study has confirmed that JEN-101 elicits potent biological activity in dogs with melanoma at doses that demonstrate good safety,” stated Rob Tighe, Chief Scientific Officer at Ankyra. He added that “the canine trial provides preliminary evidence that JEN-101 offers a therapeutic benefit in dogs with cancer and adds to the validation of our anchored therapy platform as an effective way to reduce the toxicities associated with powerful anti-tumor agents, such as IL-12.”
Under the terms of the agreement, Jenga will have an exclusive worldwide license to develop, manufacture, and commercialize JEN-101. Ankyra will receive an upfront payment and Jenga will take the lead on further development and commercialization of JEN-101. Ankyra will be eligible for regulatory and commercial milestone payments, plus royalties on worldwide sales.
Thanks Ralph,is this also one for the PYC assets please ? ANK101
Ankyra Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Dose Escalation Cohort Evaluating ANK-101, an Anchored Immune Medicine, for Solid Tumors
Safety and tolerability to be determined at up to 10 study sites in the United States and Canada
March 05, 2024 08:00 AM Eastern Standard Time
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced the first patient dosed in the dose escalation cohort in a Phase 1 clinical study evaluating ANK-101, a tumor-directed, anchored immune medicine for solid tumors
Pyc reposted this about a licensing deal between Ankyra and Jenga Bioscience with their platform JEN-101 (formerly cANK-101 (PYC helped developed.)).
https://www.linkedin.com/posts/ankyratx_ankyra-therapeutics-and-jenga-biosciences-activity-7178508921270079488-WtE0?utm_source=share&utm_medium=member_desktop
In the bloodbath of AIM hugely indebted and bloated debt companies that make no effort to grow PYC is a breath of fresh air
Compared to HZM SND etc etc
I would say it's a buy, but not particularly fussed
If they are giving 1.29 for 500k for a larger sell then could suggest some behind-the-scenes demand. Maybe Peter Sargent after a few million (joke)
Current price range is 1.23 -1.33 for modest amounts
Weather i say its a sell ,or a buy ,its what i see ...i'm sure your all old enough to make your own judgements ,so misleading is not my game...i see it how i see it ...you want to see another way feel free..,volume and price go hand in hand ,that information i'll give you for free
In the recent presentation, JM touched on the development of the PYC precision dosing tool to predict GCSF levels (currently subject to Innovate-funded trials involving Beyond Blood/Blackpool Hospital) and also mentioned that they were in discussions with Dosemerx to see whether there may be 'some way to work with them to gather more data'
I get a feeling that both Dosemerx and PYC see good potential here
Since the buy (500k)
Its now £1500 = 1.32p
£4000 = 1.35p
The 500k buy is why it's now 1 32p to buy as opposed to 1.29p at the start of the day
It's a buy msuk all 1.27p and 1.29p this week are buys
Please don't mislead
PYC now showing 'X' link to Dosemerx Precision Dosing article with this additional comment :-
'we're proud to be working alongside @DoseMeApp in advancing this field, leveraging mathematical modelling and clinical decision support software to tailor drug dosages and improve treatment outcomes for cancer patients'
I feel that we should get a decent update on progress with the Dosemerx partnership over the next few months
Interesting.
Dose me posted on twitter on 18th March, Pyc retweeted mentioning they still working with Doseme. I’m awaiting outcome of this.
https://x.com/Physiomics/status/1772939227359007009?s=20
https://x.com/Physiomics/status/1772939225266065552?s=20
Interesting you say its a sell as through Barclays the sells are at 1.23 and the buys are sub 1.333 for £100 dummy buy .. so not sure how someone got 1.29 on a 500K sell ..
Its a sell
500K buy gone through as a sell
They've been showing buys as sells (1.29p) amd tiny trades for days and werks now ..not sure why sorry
Spoke too soon. Why would someone buy £5.00 worth @ 1.40 ?
Never quite understood why market makers are prone to exaggerate the true bid-offer range. Clearly the current range here is around 1.21-1.29 and not 1.20-1.40 , as shown
Are they trying to dissuade buyers for some reason or is it just laziness on their part. Surely they are depressing interest and potentially losing some commission as a result
I assume SAR who have raised and spent £20mln+and already had 2 share consolidation and who's directors get paid £200k+!!
Wrong BB - apologies all !
Many on here said they would subscribe to a placing when the SP was at 25p ... and now it is at 14p and still nothing !!!!
Do they have a plan which does not consider shareholder value ?? ... for instance moving compounds and jobs to a new company, looking after themselves but not the shareholders ??
Have to say I am imagining dodgy dealings behind the scenes which are solely aimed at the BOD looking after themselves
Hope I am wrong !
Ýeah Truro
Another really impressive overview by Peter
Only caught up to the presentation today. Very impressed by the way Peter Sargent is working ON the business. There seems to be a real improvement in the structure and oversight. Bodes very well for the future - particularly the two newer parts that are yet to produce revenue. Good times ahead I think!